Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Study Here
Learn More
In addition to its own cadre of scientists hard at work fighting the pandemic, Johnson & Johnson also supports external researchers and entrepreneurs equally dedicated to finding solutions for the current health crisis. We take a look at some of this groundbreaking work happening across the globe—from San Francisco to Seoul.
Check out this infographic breakdown of the company’s third-quarter 2020 performance, with key highlights from its consumer, pharmaceutical and medical devices businesses.
When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.
From work on an investigational vaccine candidate to a $50 million commitment in support of healthcare workers on the very front lines of the crisis around the world, learn how the company has taken action to help respond to the pandemic.
Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.
Emmanuelle Charpentier, Ph.D., and Jennifer Doudna, Ph.D., were just honored with the prestigious award for their work with gene-editing technology CRISPR. But they also have a connection to Johnson & Johnson—they were awarded the Dr. Paul Janssen Award in 2014. Learn more about what makes them so impressive.
Live Event
The Road to a Vaccine
In Season 2 of The Road to a Vaccine, host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.
Season 2, Episode 9
Experts Weigh In On COVID-19 Testing, Vaccine Trials and More
Lisa Ling speaks with Dr. Paul Stoffels on the latest coronavirus vaccine developments. Dr. Cato Laurencin discusses why it’s critical to have diversity in clinical trials. Plus, news on possible breakthroughs in COVID-19 diagnostic testing.
-
What You're Talking About
-
Fact
In September, Johnson & Johnson launched a Phase 3 clinical trial of Janssen’s COVID-19 vaccine candidate.
Recent Johnson & Johnson Initiatives in the Spotlight
Learn more about the company’s latest groundbreaking programs, game-changing innovations and global partnerships—all aimed at helping change the trajectory of health for humanity.
